Trial design
endometriosis, PCOS, infertility, systemic disorders like metabolic syndrome, Cushing’s disease, non-obstructive azoospermia, malnutrition, diabetes
ENDOMETRIOSIS, FEMALE INFERTILITY, THYROID DISEASE, NON-OBSTRUCTIVE AZOOSPERMIA, HYPERLIPIDEMIA, CARDIOVASCULAR DISEASE, SEVERE OBESITY, OVARIAN TUMORS, MALNUTRITION, HYPERPROLACTINEMIA, AUTOIMMUNE DISEASE, DIABETES
Infertile PCOS patients aged 18–40 years were enrolled in this randomized clinical trial (RCT). They all met the Rotterdam criteriaPatients were excluded from the trial if they fulfilled any of the following criteria:Severe endometriosis (stages 3 and 4 in terms of the revised AFS-rAFS classifying the endometriosis), FSH > 10 mg/mL, hyperprolactinemia, Cushing’s disease, ovarian tumors, thyroid disease, severe male factor infertility (particularly non-obstructive azoospermia), drug history affecting ovarian function in the 3 months prior to the study (steroids and oral contraceptive pills [OCPs]), female infertility factors other than cervical and tubal factors, any autoimmune disease, systemic disorders like metabolic syndrome, severe obesity and malnutrition (body mass index [BMI] over 35), hyperlipidemia, diabetes, and cardiovascular disease.The participants were recruited from patients who were candidates for the ICSI protocol at Omid Clinic, Tehran, Iran, between November 2020 and September 2021. Although male factor indication for ICSI utilization appears to be constant, non-male factor indications remain controversial